Comparative Pharmacology
Head-to-head clinical analysis: SULFAMETHOXAZOLE versus SULTEN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMETHOXAZOLE versus SULTEN 10.
SULFAMETHOXAZOLE vs SULTEN-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Displaces dihydropteroate synthetase from its substrate para-aminobenzoic acid (PABA), inhibiting bacterial folate synthesis. Bacteriostatic against susceptible organisms.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
800 mg sulfamethoxazole with 160 mg trimethoprim (DS tablet) orally every 12 hours.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
None Documented
None Documented
9-11 hours in adults with normal renal function. Prolonged in renal impairment: up to 20-30 hours. In neonates, 6-12 hours.
Clinical Note
moderateSulfamethoxazole + Gatifloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfamethoxazole + Rosoxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfamethoxazole + Trovafloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfamethoxazole + Nalidixic acid
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Primarily renal; ~80-90% excreted unchanged in urine, with 15-30% as acetylated metabolite. Biliary/fecal <5%.
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfamethoxazole may increase the hypoglycemic activities of Nalidixic acid."